Evaluation of the efficacy of Aprepitant in vomiting of children with cancer

Efficacy and safety of Aprepitant in prevention of chemotherapy induced nausea and vomiting in oncologic patients of Mofid children’s hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200204046377N1

Enrollment

Registered

2020-04-03

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant cancer. Agranulocytosis secondary to cancer chemotherapy

Interventions

Intervention 1: Intervention group:We treat patients with 3 milligram in kilogram(maximum 120 milligram) Aprepitant and 0/15 milligram in kilogram ondansetron on the first day 5 minutes before chemoth

Eligibility

Sex/Gender

All

Age

6 Months to 17 Years

Inclusion criteria

Inclusion criteria: age between 6 month to 17 years Proven malignancy Chemotherapy regimen with moderate to severe nausea Lack of nausea and vomiting 24 hours before starting chemotherapy Lack of known long QT syndrome Lack of abdominal and pelvic radiation therapy over the past week No active infection or any uncontrolled disease associated with malignancy Absence of corticosteroids starting 72 hours prior to chemotherapy for any reason Lack of Benzodiazepine or opioid for 48 hours

Exclusion criteria

Exclusion criteria: Sensitivity to the drugs used Dissatisfaction

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: After the intervention for two days. Method of measurement: Appendix link table.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Malek

Shahid Beheshti University of Medical Sciences

fmalek7721@gmail.com+98 21 2290 5638

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026